• Citer

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

par Moreau, Philippe;Hulin, Cyrille;Talbot, Alexis;Demarquette, Hélène;Caillot, Léo;Chalopin, Thomas;Bobin, Arthur;Manier, Salomon;Leleu, Xavier;Karlin, Lionel;Caillot, Denis;Sonntag, Cécile;Feugier, Pierre;Roussel, Murielle;Gounot, Romain;Macro, Margaret;Mohty, Mohamad;Garderet, Laurent;Tiab, Mourab;Orsini-Piocelle, Frédérique;Vincent, Laure;Meuleman, Nathalie ;Fontan, Jean;Montes, Lidia;Vekemans, Marie-Christiane;Escoffre-Barbe, Martine;Eveillard, Jean-Richard;Schiano de Colella, Jean Marc;Lambert, Jérôme;Mary, Jean Yves;Fermand, Jean-Paul;Arnulf, Bertrand;Corre, Jill;Avet-Loiseau, Herve;Facon, Thierry;Harousseau, Jean-Luc;Touzeau, Cyrille;Perrot, Aurore
Référence Blood cancer journal, 15, 1, 177
Publication Publié, 2025-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.